Don Berry

560 total citations
15 papers, 194 citations indexed

About

Don Berry is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Don Berry has authored 15 papers receiving a total of 194 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 6 papers in Cancer Research and 5 papers in Molecular Biology. Recurrent topics in Don Berry's work include Cancer Genomics and Diagnostics (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Statistical Methods in Clinical Trials (3 papers). Don Berry is often cited by papers focused on Cancer Genomics and Diagnostics (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Statistical Methods in Clinical Trials (3 papers). Don Berry collaborates with scholars based in United States, United Kingdom and Australia. Don Berry's co-authors include Michael Krams, Andrew P. Grieve, Peter Müller, Michael K. Smith, Paul Gallo, Laura van ‘t Veer, Inna Perevozskaya, Alun Bedding, José Paulo Pinheiro and Smita Asare and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Don Berry

15 papers receiving 185 citations

Peers

Countries citing papers authored by Don Berry

Since Specialization

Citations

This map shows the geographic impact of Don Berry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Don Berry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Don Berry more than expected).

Fields of papers citing papers by Don Berry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Don Berry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Don Berry. The network helps show where Don Berry may publish in the future.

Co-authorship network of co-authors of Don Berry

This figure shows the co-authorship network connecting the top 25 collaborators of Don Berry. A scholar is included among the top collaborators of Don Berry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Don Berry. Don Berry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Abstract P5-13-12: Immune signatures and MammaPrint (ultra) high risk class (MP2) as predictors of response to pembrolizumab combined with the TLR9 agonist SD101 in the neoadjuvant I-SPY 2 TRIAL 2022 ·Cancer Research ·Denise M. Wolf, Christina Yau, Michael J. Campbell, Hatem Soliman, Mark Jesus M. Magbanua, Ruixiao Lu, (unknown), Lamorna Brown Swigart, Gillian L. Hirst, Laura Sit, (unknown), (unknown), Smita Asare, Douglas Yee, (unknown), Don Berry, Laura J. Esserman, (unknown), Laura van ‘t Veer	2
2	Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial 2020 ·npj Breast Cancer ·Denise M. Wolf, Christina Yau, Julia Wulfkuhle, Lamorna Brown Swigart, Rosa I. Gallagher, Mark Jesus M. Magbanua, (unknown), Gillian L. Hirst, (unknown), Smita Asare, Debu Tripathy, Don Berry, Laura J. Esserman, A. Jo Chien, Emanuel F. Petricoin, Laura van ‘t Veer	25
3	Abstract P3-10-06: Expression-based immune signatures as predictors of neoadjuvant targeted-/chemo-therapy response: Experience from the I-SPY 2 TRIAL of ˜1000 patients across 10 therapies 2019 ·Cancer Research ·Christina Yau, (unknown), Michael J. Campbell, Peter Savas, Rose Lin, Lamorna Brown Swigart, Gillian L. Hirst, Smita Asare, Zelos Zhu, Sherene Loi, Angela DeMichele, Douglas Yee, Don Berry, Laura J. Esserman, Laura van ‘t Veer	7
4	Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL 2019 ·Cancer Research ·Michael J. Campbell, Christina Yau, (unknown), Scott Vandenberg, Clifford Hoyt, Lamorna Brown Swigart, Gillian L. Hirst, Rita Nanda, Minetta C. Liu, Smita Asare, (unknown), Douglas Yee, (unknown), Don Berry, Laura Esserman, (unknown)	10
5	Abstract S2-06: DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk breast cancer 2017 ·Cancer Research ·(unknown), Christopher Yau, Ashish Sanil, Annuska M. Glas, (unknown), Julia Wulfkuhle, Lamorna Brown Swigart, Gillian L. Hirst, (unknown), (unknown), A. DeMichele, Nola M. Hylton, (unknown), Douglas Yee, Marco Paoloni, L. Esserman, Don Berry, H. S. Rugo, (unknown), (unknown)	3
6	Abstract 858: Combining sensitivity markers to identify triple-negative breast cancer patients most responsive to veliparib/carboplatin: results from the I-SPY 2 TRIAL 2016 ·Cancer Research ·Denise M. Wolf, Christina Yau, Ashish Sanil, Lamorna Brown Swigart, Gillian L. Hirst, Meredith Buxton, Melissa Paoloni, (unknown), Olufunmilayo Olopade, Hope S. Rugo, (unknown), Fraser Symmans, Don Berry, Laura J. Esserman, Laura van ‘t Veer	2
7	DNA repair deficiency biomarkers and identification of ER-positive breast cancer patients who may benefit from veliparib/carboplatin: Results from the I-SPY 2 trial. 2015 ·Journal of Clinical Oncology ·Laura van’t Veer, Laura Esserman, Ashish Sanil, Annuska M. Glas, (unknown), Sabine C. Linn, Lamorna Brown Swigart, Gillian L. Hirst, (unknown), Olufunmilayo I. Olopade, Hope S. Rugo, Don Berry, Denise M. Wolf, Christina Yau	1
8	532 Evaluation of a BRCAness signature as a predictive biomarker of response to veliparib/carboplatin plus standard neoadjuvant therapy in high-risk breast cancer: results from the I-SPY 2 trial 2014 ·European Journal of Cancer ·Annuska M. Glas, Janneke G. C. Peeters, (unknown), Denise M. Wolf, Ashish Sanil, (unknown), (unknown), Shai Linn, Meredith Buxton, A. DeMichele, Nola M. Hylton, (unknown), Douglas Yee, Marco Paoloni, L. Esserman, Don Berry, H. S. Rugo, (unknown), Laura van ‘t Veer	7
9	413 Relationship Between Body Mass Index (BMI) and Outcomes in Node-positive Breast Cancer Patients Receiving Chemotherapy–Results From CALGB/Intergroup 9741 2012 ·European Journal of Cancer ·JA Ligibel, C. Cirrincione, (unknown), (unknown), WJ Gradishar, (unknown), C. Hudis, EP Winer, Don Berry	1
10	Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944) 2008 ·Breast Cancer Research and Treatment ·Gretchen Kimmick, Constance Cirrincione, David B. Duggan, Kapil N. Bhalla, Nicholas J. Robert, Don Berry, Larry Norton, (unknown), I. Craig Henderson, Clifford A. Hudis, Eric P. Winer, (unknown)	9
11	Simulation-based sequential Bayesian design 2007 ·Journal of Statistical Planning and Inference ·Peter Müller, Don Berry, Andrew P. Grieve, Michael K. Smith, Michael Krams	49
12	Adaptive Dose-Response Studies 2006 ·Drug Information Journal ·Brenda Gaydos, Michael Krams, Inna Perevozskaya, Frank Bretz, (unknown), Paul Gallo, Don Berry, (unknown), José Paulo Pinheiro, Alun Bedding	34
13	A Bayesian Decision-Theoretic Dose-Finding Trial 2006 ·Decision Analysis ·Peter Müller, Don Berry, Andrew P. Grieve, Michael Krams	27
14	CpG Island Methylation Is a Poor Prognostic Factors in Myelodysplastic Syndrome Patients and Is Reversed by Decitabine Therapy-Results of a Phase III Randomized Study. 2005 ·Blood ·Lanlan Shen, Hagop M. Kantarjian, Hussain I. Saba, E. Lin, Don Berry, Saira Ahmed, Jaroslav Jelı́nek, Jean‐Pierre J. Issa	5
15	Subcutaneously Administered Recombinant Human Interleukin-2 and Interferon Alfa-2a for Advanced Breast Cancer: A Phase II study of the Cancer and Leukemia Group B (CALGB 9041) 2003 ·Investigational New Drugs ·Gretchen Kimmick, Mark J. Ratain, Don Berry, Susan Woolf, Larry Norton, Hyman B. Muss	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact